← Back to All Filings

Dexcom President & COO Buys $1M in DXCM Stock

Low SignificanceNovember 10, 2025 at 7:32:19 PM EST

DEXCOM INC

$DXCM4CIK: 0001093557

Subscribe to track DXCM

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Dexcom President & COO Buys $1M in DXCM Stock

Company: DEXCOM INC (DXCM) Form: 4 | Filed: 2025-11-10 Significance: Low

Insider: Leach Jacob Steven Title: President & COO | Relationship: Officer

Transaction: • Type: Buy • Shares: 18,200 • Avg Price: $55.04 • Value: $1,001,702 • Owned After (Direct): 331,697

Key Insight: A high-level executive purchase is a positive signal, but the transaction size is immaterial, representing less than 0.005% of the company's market capitalization.

Market Context: The purchase adds to the insider's existing position in the $21.45B medical device company. The overall ownership stake remains below 0.1%.

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: DEXCOM INC (DXCM)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The President & COO of Dexcom made an open market purchase of common stock totaling approximately $1 million.
  • Market Impact: The transaction is a vote of confidence from a key executive but is too small relative to the company's market capitalization to be considered a material event.

Company Information

FieldValue
CompanyDEXCOM INC
Ticker SymbolDXCM
CIK0001093557
IndustrySurgical & Medical Instruments & Apparatus

Insider Information

FieldValue
NameLeach Jacob Steven
CIK0001700255
Title/PositionPresident & COO
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-10
Transaction CodeP (Open market purchase)
Security TypeCommon Stock
Shares Involved18,200
Avg. Price Per Share$55.04
Total Value$1,001,702
Shares Owned After (Direct)331,697
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,001,702
% of Market Cap0.0047%
Shares Transacted18,200
% of Shares Outstanding0.0046%
Post-Transaction Ownership (Total)378,993 shares (0.097% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a large-cap company with a market capitalization of $21.45 billion, a $1 million transaction is not financially significant.
  • Ownership Concentration: The insider's total direct and indirect holdings after the purchase represent less than 0.1% of the total shares outstanding, indicating a very low concentration of ownership.
  • Transaction Significance: The purchase is notable due to the insider's C-suite position (President & COO), which can be interpreted as a bullish signal. However, its financial impact is negligible, as it represents a tiny fraction of both the company's market value and total shares.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: While an executive purchase is a positive sentiment indicator, the transaction's size is insufficient to materially affect the stock price of a $21.45 billion company.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The transaction is too small to cause a noticeable impact on trading volume.
  • Sentiment Indicator: Neutral. The positive signal from the insider's role is offset by the immaterial size of the trade.

Additional Context

Transaction Notes

  • Special Circumstances: The filing reports two separate purchase transactions on the same day at weighted average prices, indicating the shares were acquired in multiple trades throughout the day.
  • Insider Holdings: The insider also has indirect holdings of 47,296 shares through a family trust, bringing their total beneficial ownership to 378,993 shares.
Topics:#SECFiling#InsiderTrading#DXCM#Dexcom#Form4#InsiderBuy#StockMarket#Investing#MarketAnalysis#HealthcareTech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.